Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Zittermann A, Berthold HK, Pilz S. The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2020;74:1–8.
Lerch C, Shroff R, Wan M, Rees L, Aitkenhead H, Kaplan Bulut I, et al. Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrol Dial Transpl. 2018;33:2208–17.
Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, et al. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2014;99:3103–11.
Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672–9.
Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol. 2015;10:611–9.
Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens. 2012;25:1215–22.
Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. BMC Nephrol. 2013;14:163.
Turrini F, Scarlini S, Giovanardi P, Messora R, Roli L, Chester J, et al. Effects of Cholecalciferol Supplementation in Patients with stable heart failure and LOw vITamin D levels (ECSPLOIT-D): a double-blind, randomized, placebo-controlled pilot study. Minerva Cardioangiol. 2017;65:553–62.
Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44:316–25.
Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, et al. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1‐year double‐blind RCT in postmenopausal women. J Bone Min Res. 2013;28:2202–13.
Higgins JPTGS, editor. 16.5.4 How to include multiple, for gfosIICh, systematic reviews of interventions vTC, from: CcDA, https://handbook-5-1.cochrane.org/chapter_16/16_5_4_how_to_, include_multiple_groups_from_one_study.htm.
Trummer C, Schwetz V, Pandis M, Grübler MR, Verheyen N, Gaksch M, et al. Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. Eur J Nutr. 2019;58:697–703.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Meshkini, F., Soltani, S., Clayton, Z.S. et al. The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr (2021). https://doi.org/10.1038/s41430-021-00903-8